Sweden · Delayed Price · Currency is SEK Mentice AB Earnings Call Transcripts
Fiscal Year 2026
-
The presentation highlighted strong growth in simulation solutions for minimally invasive procedures, with a broadened customer base and robust financial performance. Strategic investments in advanced training and digital twin technology aim to drive further expansion and profitability.
Fiscal Year 2025
-
Q4 saw strong organic growth in sales and order intake, with EBITDA margin rising to 25%. The Americas and MDI segment led performance, while cost control and R&D focus position the company for continued growth in 2026.
-
Q3 saw 22% year-over-year net sales growth, driven by the medical device industry in Americas and EMEA, with improved EBITDA margin from cost reductions. A successful rights issue and the launch of a portable simulation system support future growth, while hospital and APAC segments face challenges.
-
Q2 net sales declined 33% year-over-year due to a strong prior-year comparison and cautious market, but cost-saving measures and new product clearances position the business for improved profitability and growth in the second half. Rights issue to raise SEK 32 million is well supported.
-
Net sales grew 19.5% year-over-year, driven by strong performance in Americas and APAC, while EBITDA was impacted by restructuring and currency effects. Medical device industry order intake surged, but Healthcare Systems lagged and is being addressed.
Fiscal Year 2024
-
Q4 2024 delivered 22.4% net sales growth year-over-year, with strong EMEA and APAC performance and a 19.1% EBITDA margin. Full-year sales rose 6%, and software-driven gross margin improvements set a positive outlook for 2025.
-
Q3 net sales declined 10% year-over-year to SEK 58 million, with APAC growth offset by declines in Americas and EMEA. EBITDA was negative for the quarter but break-even year-to-date, and two major post-quarter orders are expected to support future growth.